MG
LENZ

Michael Gelband’s LENZ Therapeutics LENZ Stock Holding History

Michael Gelband’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-57,577
Closed -$527K – 2163
2026
Q1 		$527K Buy
57,577
+34,430
+149% +$484K ﹤0.01% 1179
2025
Q4 		$370K Buy
+23,147
New +$675K ﹤0.01% 1254
2025
Q2 		– Sell
-27,829
Closed -$715K – 2053
2025
Q1 		$715K Buy
+27,829
New +$685K 0.01% 1014
2022
Q4 		– Sell
-1,834
Closed -$41K – 2222
2022
Q3 		$41K Buy
+1,834
New +$43.7K ﹤0.01% 1798

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Michael Gelband's LENZ Position: Q2 2026 in Review

Michael Gelband sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 57,577 shares — an estimated $527K sold.

Michael Gelband first reported a position in LENZ in Q3 2022 and held it in 4 quarters. The position peaked at $715K in Q1 2025. 143 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Michael Gelband reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 57,577 LENZ Therapeutics shares in Q2 2026, an estimated $527K.
  • Michael Gelband first reported a position in LENZ Therapeutics in Q3 2022 and held it in 4 quarters.
  • Michael Gelband's LENZ Therapeutics position peaked at $715K in Q1 2025.
  • 143 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.